Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CHILDREN S CETIRIZINE HYDROCHLORIDE HIVES RELIEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus CHILDREN S CETIRIZINE HYDROCHLORIDE HIVES RELIEF.
ACUVUE THERAVISION WITH KETOTIFEN vs CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Cetirizine is a selective histamine H1-receptor antagonist. It inhibits the H1 receptor, reducing histamine-mediated effects such as edema, flare, and pruritus.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
5 mg or 10 mg orally once daily; maximum 10 mg per day.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Terminal elimination half-life is approximately 8.3 hours in healthy adults; prolonged to ~20 hours in renal impairment (CrCl <30 mL/min).
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 10% is eliminated in feces.
Category A/B
Category A/B
Antihistamine / Mast Cell Stabilizer
Antihistamine